BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Core Insights - BriaCell Therapeutics Corp. announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive, HER2-negative metastatic breast cancer treated with Bria-OTS, a personalized off-the-shelf immunotherapy [1][2]. Group 1: Clinical Results - The first patient in the Bria-OTS study, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis after four doses of Bria-OTS monotherapy, confirmed at two, four, and six months [2][3]. - The patient has received a total of 12 cycles of Bria-OTS to date, with no treatment-limiting toxicities observed [6]. Group 2: Expert Commentary - Dr. Neal S. Chawla, Principal Investigator for the Bria-OTS study, highlighted the strong single-agent activity in a challenging patient population and expressed eagerness to explore this approach across more patient subtypes and tumors [5]. - Dr. William V. Williams, BriaCell's President and CEO, emphasized the remarkable and durable clinical response, particularly at the lowest dose level, and indicated plans to evaluate Bria-OTS in combination with a checkpoint inhibitor to enhance outcomes for patients with advanced breast cancer [5]. Group 3: About Bria-OTS - Bria-OTS is a next-generation, off-the-shelf personalized immunotherapy based on BriaCell's lead candidate, Bria-IMT, currently in a Phase 1/2a study for metastatic recurrent breast cancer, which includes both monotherapy dose escalation and combination dose expansion cohorts [7].